New knowledge about a potential pathway for cancer therapies

02/10/2018

Centenary Institute scientists have discovered dozens of new likely targets for a particular enzyme (FAP) that is within most tumours; paving the way for the future development of safer and more effective cancer therapies, including liver, lung, skin, colorectal and pancreatic cancers.

Instead of affecting and interacting with just collagen, the researchers have used new technologies to identify 37 molecules which FAP likely modifies.

Co-lead author, Dr Hui Emma Zhang from the Centenary Institute, says this study not only reaffirms the value of FAP in cancer research, but it also provides new avenues through which scientists can target tumour growth.

“Given FAP is fairly unique to damaged cells when compared to healthy cells, the findings from our research will enhance the initial identification and imaging of tumours, as well as provide a safer and more targeted pathway through which anti-cancer therapies can be delivered,” says Dr Zhang.

See the full media release.

Read Identification of Novel Natural Substrates of Fibroblast Activation Protein-alpha by Differential Degradomics and Proteomics in Molecular and Cellular Proteomics.

Pictured: A human liver tumour (large pale cells) surrounding a peninsular of stromal cells (dense blue), with FAP molecules stained dark brown.

Latest News

Leading respiratory scientist recognised for research excellence

Centenary Institute - Medical Research

The Thoracic Society of Australia and New Zealand bestows one of their most prestigious awards to Professor Phil Hansbro.

World Health Organisation (WHO) visits Centenary

Centenary Institute - Medical Research, Tuberculosis Research

WHO and the regional Green Light Committee at Centenary hosting regional tuberculosis control training.

Spirit of a community raising funds to help save lives

Community Fundraising Centenary Institute

Bellingham Cup honours a much loved young man and raises awareness for our Molecular Cardiology Program

 

News Topics

ALL NEWS
//